A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies

Anne-Marie Chaftari, Ray Hachem, Alexandre E Malek, Victor E Mulanovich, Ariel D Szvalb, Ying Jiang, Ying Yuan, Shahnoor Ali, Rita Deeba, Patrick Chaftari, Issam Raad, Anne-Marie Chaftari, Ray Hachem, Alexandre E Malek, Victor E Mulanovich, Ariel D Szvalb, Ying Jiang, Ying Yuan, Shahnoor Ali, Rita Deeba, Patrick Chaftari, Issam Raad

Abstract

Background: With increased use of antibiotics in high-risk patients, the investigation of new antibiotics to cover potentially resistant pathogens is warranted. In this prospective randomized trial, we compared ceftolozane/tazobactam (C/T), a new cephalosporin/β-lactamase inhibitor, to the standard of care (SOC) for the empiric treatment of neutropenia and fever in patients with hematological malignancies.

Methods: We enrolled 100 patients to receive intravenous (IV) C/T or SOC antibiotics (cefepime, piperacillin/tazobactam, or meropenem) in combination with gram-positive antibacterial agents. We evaluated responses at the end of IV therapy (EOIV), test of cure (TOC; days 21-28), and late follow-up (LFU; days 35-42).

Results: We analyzed 47 C/T patients and 50 SOC patients. C/T patients had a higher rate of favorable clinical response at EOIV (87% vs 72%). A 1-sided noninferiority analysis indicated that C/T was at least not inferior to the SOC for favorable clinical response at EOIV (P = .002), TOC (P = .004), and LFU (P = .002). Superiority tests showed that C/T led to significantly lower rates of clinical failure at TOC (6% vs 30%; P = .003) and LFU (9% vs 30%; P = .008). C/T and SOC patients with documented infections had similar rates of favorable microbiological response. Serious adverse events leading to drug discontinuation (2% vs 0%; P = .48) and overall mortality (6% vs 4%; P = .67) were similar in both groups.

Conclusions: The empiric use of C/T in high-risk patients with hematological malignancies and febrile neutropenia is safe and associated with better clinical outcomes than SOC antimicrobial agents.

Clinical trials registration: NCT03485950.

Keywords: cancer patients; febrile neutropenia; fever; immunocompromised; leukemia; neutropenia; neutropenic fever.

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Study design. Abbreviations: IV, intravenous; LFU, late follow-up; SOC, standard of care; TOC, test of cure.
Figure 2.
Figure 2.
Patient population and analysis sets. Abbreviations: CE, clinically evaluable; EOIV, end of intravenous therapy; IV, intravenous; mMITT, microbiological modified intention-to-treat; TOC, test of cure.

References

    1. Zuckermann J, Moreira LB, Stoll P, Moreira LM, Kuchenbecker RS, Polanczyk CA.. Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol 2008; 87:139–45.
    1. Freifeld AG, Bow EJ, Sepkowitz KA, et al. . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56–93.
    1. Lodise TP Jr, Patel N, Kwa A, et al. . Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007; 51:3510–5.
    1. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH.. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306–11.
    1. Rottier WC, Ammerlaan HS, Bonten MJ.. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother 2012; 67:1311–20.
    1. Martinez-Nadal G, Puerta-Alcalde P, Gudiol C, et al. . Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance. Clin Infect Dis 2020; 70:1068–74.
    1. Gudiol C, Albasanz-Puig A, Laporte-Amargos J, et al. . Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 2020; 64:e02494-19.
    1. Averbuch D, Tridello G, Hoek J, et al. . Intercontinental study on pre-engraftment and post-engraftment gram-negative rods bacteremia in hematopoietic stem cell transplantation patients: risk factors and association with mortality. J Infect 2020; 81:882–94.
    1. Trecarichi EM, Tumbarello M.. Antimicrobial-resistant gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis 2014; 27:200–10.
    1. Irfan S, Idrees F, Mehraj V, Habib F, Adil S, Hasan R.. Emergence of carbapenem resistant gram negative and vancomycin resistant gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infect Dis 2008; 8:80.
    1. Montassier E, Batard E, Gastinne T, Potel G, de La Cochetiere MF.. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis 2013; 32:841–50.
    1. Pagano L, Caira M, Rossi G, et al. . A prospective survey of febrile events in hematological malignancies. Ann Hematol 2012; 91:767–74.
    1. Hansen BA, Wendelbo O, Bruserud O, Hemsing AL, Mosevoll KA, Reikvam H.. Febrile neutropenia in acute leukemia. epidemiology, etiology, pathophysiology and treatment. Mediterr J Hematol Infect Dis 2020; 12:e2020009.
    1. Gustinetti G, Mikulska M.. Bloodstream infections in neutropenic cancer patients: a practical update. Virulence 2016; 7:280–97.
    1. Cluck D, Lewis P, Stayer B, Spivey J, Moorman J.. Ceftolozane-tazobactam: a new-generation cephalosporin. Am J Health Syst Pharm 2015; 72:2135–46.
    1. Solomkin J, Hershberger E, Miller B, et al. . Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 2015; 60:1462–71.
    1. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO.. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385:1949–56.
    1. Lucasti C, Hershberger E, Miller B, et al. . Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2014; 58:5350–7.
    1. Kollef MH, Novacek M, Kivistik U, et al. . Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2019; 19:1299–311.
    1. Fernandez-Cruz A, Alba N, Semiglia-Chong MA, et al. . A case-control study of real-life experience with ceftolozane-tazobactam in patients with hematologic malignancy and Pseudomonas aeruginosa infection. Antimicrob Agents Chemother 2019; 63:e02340-18.
    1. Hakki M, Lewis JS 2nd. Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients. Infection 2018; 46:431–4.
    1. Clerici D, Oltolini C, Greco R, et al. . The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia. Int J Antimicrob Agents 2021; 57:106335.
    1. Klastersky J, Ameye L, Maertens J, et al. . Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007; 30:S51–59.
    1. Farrell DJ, Flamm RK, Sader HS, Jones RN.. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob Agents Chemother 2013; 57:6305–10.
    1. Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN.. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12). J Antimicrob Chemother 2014; 69:2713–22.
    1. Sader HS, Farrell DJ, Flamm RK, Jones RN.. Ceftolozane/tazobactam activity tested against aerobic gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect 2014; 69:266–77.
    1. Walkty A, Karlowsky JA, Adam H, et al. . In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob Agents Chemother 2013; 57:5707–9.
    1. Sutherland CA, Nicolau DP.. Susceptibility profile of ceftolozane/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from US hospitals. Clin Ther 2015; 37:1564–71.
    1. Tato M, Garcia-Castillo M, Bofarull AM, Canton R.. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: results of the CENIT study. Int J Antimicrob Agents 2015; 46:502–10.
    1. Estabrook M, Bussell B, Clugston SL, Bush K.. In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum beta-lactamases. J Clin Microbiol 2014; 52:4049–52.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit